Just spent 10 hours straight at KeyBank’s Emerging Technology Summit with institutional investors in big tech. The #1 obsession? Agentic Commerce. The biggest DTC shopping shift in history. My POV and what's on everyone's mind 👇

Musecase of the day👇 Woke up w/ HVAC broken. Couldn’t find the guy’s contact who last came to work on the unit. Then I had Muse go search my Gmail inbox bc I couldn’t find it in Gmail’s shit search function or my iPhone contacts. Two minutes later, Muse found the vendor, saved the contact in my iPhone and texted to schedule my appointment for 12pm today. Painless.

Meta's Muse is on another level 🚀 $META

Muse capping off Meta's generational comeback in the AI race.

If only Muse could figure out how to log me in to TikTok Shop & Meta each day without me needing to grab the 2FA's and solving origami puzzles, that would really be something else.

Not all heroes wear capes. Some wear red bikinis. Muse bringing $META back to life 📈

The people arguing with me on this statement are also likely the same people who gave 23andMe their entire genetic code 😂 23andMe sold your DNA for $20 a pop.

Is Meta in the midst of its best 7-day stretch in recent memory? With the launch of Muse, consensus sentiment feels like it’s never been this rosy. Makes you think back to all the earnings calls over the last few quarters where Meta got slaughtered for CAPEX. Comical to think that Zuck knew all along this is what it was leading up to. He’s sitting in a dark room somewhere chuckling… aMused. $META price targets are now skyrocketing for the same reason it was getting torched in the past. The stock is UNDERVALUED.

Soon your Muse will have its own email address so it can shamelessly act on your behalf to chase discounts 😂 Your human reputation stays clean while Muse handles the dirty work. Curious how this impacts how customer support treats Muse v human interactions.

Introducing Musecharm. Meta just announced that you’ll be able to talk to Muse through this little keychain. Releasing in December. This is brilliant. Meta keeps winning.

People saying "I'd never give Muse/Meta access to my Gmail, Calendar, etc" is the 2026 version of "I'll never put my credit card on the internet."

I still prefer Claude to Muse for most business use cases. Cowork taking over my current browser is less painful than having to log Muse in to a variety of different tools for each task.

the ONE thing I haven't been impressed w/ on Muse has been phone calls. No customer service agent will take an AI agent seriously on a phone call. I've tried it. Well, well... seems like Meta already has a solution in store...

Interesting... this kind of puts a damper on the Shop Pay integration, no? There will undoubtedly be some sort of incentive Meta will give users to use Meta Pay.

Sales tax is the unsexiest problem in ecommerce. It is also one of the ones that bites hardest as you scale. We've had clients come to us not collecting sales tax in states where they've had nexus, with millions of dollars in liabilities. Forget ambulance-chaser lawyers for ADA compliance and the California Invasion of Privacy Act; the last thing you want is State tax collectors breathing down your neck... they don't just go away. We've outsourced this problem for our clients to Numeral, who just raised a $100M Series C. The moment a brand starts growing, it owes compliance in every state where it crosses nexus. Registrations, filings, remittance, exemption certificates, plus physical mail from dozens of departments of revenue. Miss one filing and you eat penalties and interest. No founder or finance team should spend time on that in ecommerce. Numeral is the done-for-you solution. Registrations, filings, mail handling, product classification, handled end-to-end. Congrats to the entire Numeral team! Not having to think about sales tax ever again is a blessing for any e-commerce brand, and this latest round underscores that.

Shopify now showing Muse as an Agentic sales channel in its UI. Shopify Catalog now giving Muse your product data. Make sure it's structured properly! I expect "Meta AI and Muse" attributed revenue to surpass ChatGPT for most brands in the next few months.

Meta being crafty here with the Muse token signup bonus (1 billion for free)... Simply inviting users w/ your invite link isn't enough. It doesn't have any URL parameters.. aka no referral code passed through. Aka you get no signup bonus. After your referral signs up, they are 3 clicks away from you or them getting any bonus: must click the hamburger menu, then settings, then "redeem referral code." I guarantee 90%+ of new signups did not go through these steps and never claimed their 1 billion free tokens. Oh and you must enter it within 48 hours of signup or you lose the option to redeem your code. @alexandr_wang lets get this changed!

The more I use Muse, the more I'm convinced it will beat ChatGPT and others for consumer use. It's already my favorite agentic experience for personal use. ChatGPT won answers, it replaced Google for questions. Muse is about to replace it for discovery, and that's where the real money is. Attention with intent is the most valuable inventory on the internet. No lab can replicate billions of creators as a ranking signal. Meta's moat was never the model, it's the graph: billions of creators posting content in their own niches... ranked by engagement instead of SEO games. Muse differentiates in a unique way through the power of social search. It has the largest social graph of any platform in the world and now gets to put it to use. Muse becomes a revved up version of IG & FB search. Why is this useful? AEO on ChatGPT and others can be gamified through strategic content & placements. AEO on Muse leans into influencer mentions and engagement on Reels... something no other LLM is effective at doing with IG and FB content. So for the average consumer looking for that trendy new restaurant in their city or a specific product to solve a need... Muse becomes that trusted advisor where consumers typically turn to first for recommendations... IG & FB influencers. Take a look at this Musecase that no LLM (or search engine) has effectively executed before for me👇 I asked Muse for the best happy hour near me w/ IG reference videos from foodie influencers. Next step from here would be to have Must book the reservation for me with one message. Try this in ChatGPT... you won't get the IG reels data which is arguably the most influential part of the research & resulting response. If you thought IG and FB influencer was a fast-growing market before... look out. It's about to accelerate at warp speed.

Been playing around with Muse, I'm impressed. I prefer Claude for business, but Muse is probably my favorite for personal use already. What's crazy is that it's free (for the vast majority of users)... Right now, Meta is NOT monetizing the app other than paid subscription tiers which really only apply to power users (just to cover compute). So what's really in it for Meta down the road? 🤔 - Infinite user data to influence ad targeting - New ad inventory real estate - Commerce transaction fees 1/ Data for ad targeting Meta is building an absolute treasure trove of deeply personal data on users who are now chatting with Muse and connecting their email, payments, calendars, etc. Muse can see your inbox (products you buy, trips you take, your life stage, what you do for work, the newsletters you read), your payment and spending activity, and the tasks you hand it (what you're dealing with right now). The list goes on. Meta says Muse data isn't used in its ads system... for now. But if and when it is? Forget it. That's how Meta's already world-class ads algo gets another lift. Targeting will be on another level. 2/ Ad inventory Meta is building tons of new real estate for eventual ad placements. I think this is at least a year out, since user adoption is the priority right now. 3/ Commerce take rates Muse is already personal shopping for users. As far as I know, it doesn't take a cut from Shopify merchants on the transactions it facilitates today, but that could easily change if it proves it can drive incremental revenue for brands. EXCITING TIMES.

At midnight on February 6th, earlier this year, the doorbell to our apartment rang. The doorbell was followed by a pounding on the door. I answered the door and a security person in our building handed me his phone. It was my oldest daughter Eloise. She had found my 26-year-old daughter unconscious on the floor of her apartment and had called 911. The EMT team was already there, but they did not know what was wrong with Lucy or to which hospital they would take her. I threw on some clothes and jumped in an Uber heading east toward Brooklyn. (Lucy lived alone in Williamsburg.) On the way, I learned that they were taking her to Elmhurst, a City trauma hospital in Queens. I arrived about five minutes after the ambulance to join Eloise, Lucy’s mom, and a friend, and waited to learn what was wrong. After about 15 minutes, I asked a nurse where she was. I looked over his shoulder to his computer. Next to her name, it said “non-responsive.” I walked into the emergency room and wandered around looking for her until I found her unconscious on a gurney surrounded by several doctors and nurses. By about 2:30am with the results from a CAT scan, Lucy’s doctors had determined that she had a massive brain hemorrhage and would need an emergency hemicraniectomy to release the pressure on her brain and remove the blood from the hemorrhage. I called our wonderful friend and family doctor Eddie Fisher and explained what was going on. He woke up Josh Bederson, Chairman of Neurosurgery at Mount Sinai, to find out more about Zach Hickman, the neurosurgeon on call that night. Dr. Bederson said Hickman was an excellent surgeon, which was comforting as we had no choice. The surgery to save Lucy’s life began around 3:15am and finished around 5:30am. It was successful. The following day, I joined Lucy in an ambulance while she was being transferred to Mount Sinai on Madison Avenue. Later that day, we determined from Lucy’s Oura ring that her hemorrhage had occurred around 9am, which meant that more than 19 hours had passed from the time of the hemorrhage to the completion of the surgery to release the pressure on her brain (I only wish @ouraring had an alert for this kind of a medical event. Imagine it could call a family member if the wearer doesn’t cancel the alert). I later learned that the standard of care is not to do surgery to save a patient with a large brain bleed if more than five hours have passed since the hemorrhage. Even when the surgery is done, I was told that the likely outcome for the patient is a few months in a nursing home and death from pneumonia. When I met Lucy’s doctors, I did my best to inspire them: “Let’s see what can be accomplished if we give her the best care possible and we invest unlimited resources to restore her to life.” And I promised that whatever we learned we would make available to everyone. Dr. Chris Kellner, her neurosurgeon, and Dr. David Putrino, Director of Rehabilitation Innovation for the Mount Sinai Health System have led Lucy’s care team since that day. Words cannot describe the remarkable and compassionate care that she has received beginning with the EMT team and then from nurses, doctors, therapists, and the army of people who have worked to save her and return her to life. To this day, we have a daily Zoom where we discuss her progress and make adjustments to her care. While her care and oversight have been incredible, the learnings for the Mount Sinai team have also been elucidating and will assist in the care of many others. Lucy began in a bad place. She was in a coma for several weeks and then awoke not being able to breathe on her own, unable to walk, see or speak. Over the last six months, she has recovered her cognition – she understands everything including her circumstance – is able to walk a hundred or more steps at a time with assistance, is making progress with sounds, vowels and consonants and the beginnings of speech, but she remains unable to see. Each day, she makes a little progress, and daily progress compounds. Every day I tell her that she just needs to make a little progress and it won’t be long before she is back. We remain optimistic that Lucy will return to normal function. It will likely take years, but I believe it is only a matter of time, hard work, and technological progress, along with some, and perhaps a lot, of divine intervention. Many people have been praying for Lucy and we are incredibly grateful for the prayers and remarkable support she has received. Lucy’s friends have been with her every day since the beginning, and their presence and friendship have saved her life and helped to rebuild and maintain her spirit. And on a very positive note, Lucy’s challenge has brought together our entire modern family who have all been incredibly devoted to her care and recovery. Lucy's vision and other faculties may require some form of brain computer interface, work that is underway at Neuralink, Precision Neuroscience, Science, Synchron, Nudge, and other companies in the space. If you are going to have a devastating brain injury, now is the best time in history for that to happen. We are living in a world when you can be confident that the blind will soon see again. We are going to do everything we can to help make that happen, including by assisting existing companies in the space. With respect to our promise to make Lucy’s care available to others, we have made good progress. In May, a real estate colleague made me aware of a 93% vacant, brand new, 400,000 square foot Class A+ purpose-built biotech facility on West End Avenue between 65th and 66th Streets that missed the market and was available for sale. The Pershing Square Foundation acquired the building 60 days later. We also put under contract an adjoining 130,000 square foot building at 320 West 66th Street that is currently being used by Saturday Night Live for studio space. The building has 35-foot ceilings with massive column-free spaces that can be converted into superb rehabilitation facilities. We will close on the SNL building in December. We are also acquiring an adjoining vacant lot with additional air rights. With just the existing zoning rights, we can add a 150,000 square feet for a total of 680,000 square feet, a lab footprint larger than Rockefeller University, and that’s without including the potential for an upzoning that would allow for substantially more buildable area on the site’s 3.4 acres with spectacular views of the Hudson. Our goal is to build the world’s greatest brain research, rehabilitation, recovery, human optimization, and longevity institute. We have named it The Ackman Oxman Institute or the AOI for lack of a better name, but also to reinforce the point that Neri and I and our family are all-in on the mission. The AOI will be patient-centric. It will not be an academic research institute that produces lots of papers, a Nobel Prize winner or two, but little if any results for patients. We will be laser-focused on cures, treatments, devices, rehabilitation and exercise equipment, and targeted and basic research with a goal of massively accelerating the time from idea to innovation to production to helping a patient. While the AOI will be a non-profit, it will have highly commercial instincts. The AOI will have its own venture funding and will work to develop innovations to create companies that we will seed, assist, and spinout to ensure technologies, treatments, techniques, and drugs get to patients as promptly as possible. On one 3.4 acre campus in what is still the greatest city in the world, we will do neurosurgery, neuroscience, rehabilitation, nutrition, BCI and device development, human trials, hyperbaric oxygen treatments, and life extension programs, and we will mandate and incentivize collaboration among the teams with no silos, politics, bureaucracy, or any other constraint that is inconsistent with the mission. Mount Sinai will be an important partner and deservedly so, but it won’t be our only hospital or medical school partner as we don’t believe any institution has a monopoly on the best ideas or the best talent. We don’t believe in exclusive relationships because that is not in the best interest of patients. Five years ago, we considered launching a brain institute inspired by Neri’s mom who sadly died from Alzheimer’s. We couldn’t make the math work as the real estate was too expensive and we believed it would be too difficult to recruit the best talent from universities to our effort. Since then, the real estate became available at a 70% discount, universities became a much less attractive place to work due to politics outweighing meritocracy, protests that disrupt learning, the curse of antisemitism, and a decline in funding. Fortunately, during the same time, I made sufficient personal economic progress to make the AOI possible. The advance of AI in the last few years will also enable us to greatly accelerate our mission. AI still has a lot to learn about human intelligence and the brain, and the AOI should be at the forefront of the interplay between the brain and AI. Today, I am making a public filing disclosing a gift from Neri and me of ~$400 million or 10,000,000 shares of Pershing Square Inc. (PS) to the AOI. It is very early days for Pershing Square so these shares are intended to anchor the long-term work of the AOI as the shares compound over time while generating what we expect will be a growing stream of quarterly dividends to fund the Institute. We will also be announcing an additional gift of similar and potentially greater size which won’t be in the form of Pershing Square stock to provide the AOI with the short- and intermediate-term runway necessary to enable it to achieve its goal of becoming a self-sustaining institute, which reinvests all of its revenues, royalties, and the economic rewards of company formation to advance the fields of brain health and human longevity. Neri and I have chosen to anchor the funding of the AOI to maintain vision alignment and limit the need for the organization to focus on fundraising. We expect the AOI to be the best-resourced brain, rehab, recovery, and longevity institute in the world. We are grateful to have been able to form a board which includes Dean Kamen (our generation’s Thomas Edison), George Yancopoulus (CEO of Regeneron), James Rothman (Nobel Laureate), Bernardo Sabatini (neuroscientist), Chris Kellner (neurosurgeon), Olivia Flatto (CEO Pershing Square Foundation), Neri Oxman, and myself. We have recently identified a CEO who we expect to announce by October along with other key hires, and are beginning searches for a Chief Scientific Officer, a Chief AI/Technology Officer, a Chief Operating Officer, a Chief Financial Officer, and other key leadership roles. If you find what we are building compelling and want to be part of the leadership team that creates and builds the AOI from a standing start, please send an email to: search@aoiinst.org with a short note as to why you believe you can help. Please include your best three ideas for the AOI along with a summary of your background and your most important accomplishments. We promise strict confidentiality to those expressing interest in working with us. We have learned from Lucy that the brain can recover from even catastrophic injury. There is so much more work to be done as the mind is a terrible thing to waste. For details from my Pershing Square SEC filing see: sec.gov/Archives/edgar/data/…

Jeeeeeze have yourself a day Shopify 📈